JERUSALEM, April 17, 2013 /PRNewswire/ —

SafeCode Drug Technologies Corp. (OTCBB: SAFC), a developer of technologies that reduces errors and eliminates pain during the administration of prescription medications, announced today that the company intends to hire a Project Manager to oversee and implement a marketing strategy to commercialize its newly acquired painless injection device.

The company’s new technology is fully approved by the Federal Drug Administration (FDA), and has demonstrated itself to be safe and effective in actively reducing pain during the administration of blood tests, lanching and injections – a daily reality for many during ongoing medical care.

Both EZJect and Quickool – the newly acquired technologies – received FDA approval for commercialization in 2007.

“To acquire technology that already has FDA approval, is a major step toward full commercialization in the United States,” said Akiva Schonfled, Chief Executive Officer of SafeCode Drug Technologies. “These technologies have applications in hospitals, doctor’s offices and clinics, in addition to the at-home, individual care markets. We are confident that with the right project manager in place, we can implement a winning commercialization strategy.”

About SafeCode Drug Technologies

SafeCode Drug Technologies is the developer of patent-pending technologies that reduce errors and eliminate pain during the administration of prescription medications. The company’s initial technology is voice-activated administration technology that ensures the proper medication is administered to the proper patient. The company’s newly acquired EZJect technology eliminates pain during blood tests and injections.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of SafeCode Drug Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. SafeCode Drug Technologies Corp. public filings may be viewed at http://www.sec.gov.

Contact:
CEO, Akiva Schonfled
+9722-582-0394

SOURCE Safecode Drug Technologies Corp.